Viracta Therapeutics, Inc. (NASDAQ:VIRX) Short Interest Update

Viracta Therapeutics, Inc. (NASDAQ:VIRX) was the target of a significant decline in short interest in January. As of January 31st, there was short interest totalling 184,200 shares, a decline of 25.1% from the January 15th total of 246,000 shares. Approximately 0.7% of the company’s stock are short sold. Based on an average trading volume of 2,680,000 shares, the short-interest ratio is currently 0.1 days.

Viracta Therapeutics Price Performance

Shares of NASDAQ VIRX traded up $0.00 during mid-day trading on Friday, reaching $0.02. The company’s stock had a trading volume of 734,115 shares, compared to its average volume of 1,604,092. Viracta Therapeutics has a 52 week low of $0.01 and a 52 week high of $1.31. The stock has a fifty day moving average of $0.15 and a two-hundred day moving average of $0.21. The firm has a market capitalization of $679,554.00, a PE ratio of -0.02 and a beta of 0.70.

Institutional Trading of Viracta Therapeutics

An institutional investor recently bought a new position in Viracta Therapeutics stock. Stonepine Capital Management LLC acquired a new stake in shares of Viracta Therapeutics, Inc. (NASDAQ:VIRX) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 500,000 shares of the company’s stock, valued at approximately $116,000. Stonepine Capital Management LLC owned 1.27% of Viracta Therapeutics at the end of the most recent reporting period. 31.37% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

VIRX has been the subject of a number of analyst reports. Rodman & Renshaw reaffirmed a “neutral” rating and set a $0.25 price objective (down previously from $3.50) on shares of Viracta Therapeutics in a research report on Friday, December 27th. Royal Bank of Canada decreased their target price on shares of Viracta Therapeutics from $4.00 to $2.00 and set an “outperform” rating for the company in a research note on Thursday, November 14th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, Viracta Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $4.05.

Viracta Therapeutics Company Profile

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.